JP2022550390A - ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー - Google Patents

ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー Download PDF

Info

Publication number
JP2022550390A
JP2022550390A JP2022519662A JP2022519662A JP2022550390A JP 2022550390 A JP2022550390 A JP 2022550390A JP 2022519662 A JP2022519662 A JP 2022519662A JP 2022519662 A JP2022519662 A JP 2022519662A JP 2022550390 A JP2022550390 A JP 2022550390A
Authority
JP
Japan
Prior art keywords
hir2
dko
mef
irhom2
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550390A5 (https=
Inventor
マティーアス シュナイダー
ケルスティン ゼーレ
イェンス ルーエ
ギーセラ ウェスカンプ
カール ブローベル
Original Assignee
スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング
ニューヨーク ソサイアティ フォー ザ リリーフ オブ ザ ラプチャード アンド クリップルド メインテイニング ザ ホスピタル フォー スペシャル サージェリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング, ニューヨーク ソサイアティ フォー ザ リリーフ オブ ザ ラプチャード アンド クリップルド メインテイニング ザ ホスピタル フォー スペシャル サージェリー filed Critical スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022550390A publication Critical patent/JP2022550390A/ja
Publication of JP2022550390A5 publication Critical patent/JP2022550390A5/ja
Priority to JP2025131956A priority Critical patent/JP2025179064A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022519662A 2019-09-30 2020-09-30 ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー Pending JP2022550390A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131956A JP2025179064A (ja) 2019-09-30 2025-08-07 ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19200589 2019-09-30
EP19200589.0 2019-09-30
PCT/EP2020/077346 WO2021064009A1 (en) 2019-09-30 2020-09-30 Protein binders to irhom2 epitopes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131956A Division JP2025179064A (ja) 2019-09-30 2025-08-07 ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー

Publications (2)

Publication Number Publication Date
JP2022550390A true JP2022550390A (ja) 2022-12-01
JP2022550390A5 JP2022550390A5 (https=) 2023-10-11

Family

ID=68104520

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519662A Pending JP2022550390A (ja) 2019-09-30 2020-09-30 ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー
JP2025131956A Pending JP2025179064A (ja) 2019-09-30 2025-08-07 ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131956A Pending JP2025179064A (ja) 2019-09-30 2025-08-07 ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー

Country Status (7)

Country Link
US (1) US20240287172A1 (https=)
EP (1) EP4037699A1 (https=)
JP (2) JP2022550390A (https=)
CN (1) CN115151270A (https=)
AU (1) AU2020360849A1 (https=)
CA (1) CA3151450A1 (https=)
WO (1) WO2021064009A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510415A (ja) 2021-03-01 2024-03-07 スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング ｉＲｈｏｍ２に対するヒト化抗体
US20240174744A1 (en) * 2021-03-29 2024-05-30 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
JP2017522540A (ja) * 2014-05-09 2017-08-10 ザ ジャクソン ラボラトリーＴｈｅ Ｊａｃｋｓｏｎ Ｌａｂｏｒａｔｏｒｙ ｉＲＨＯＭポリペプチドの活性を変化させる化合物を同定する方法及びその使用
JP2022525239A (ja) * 2019-04-09 2022-05-11 ニューヨーク ソサイアティ フォー ザ リリーフ オブ ザ ラプチャード アンド クリップルド メインテイニング ザ ホスピタル フォー スペシャル サージェリー ｉＲｈｏｍ２のタンパク質バインダー

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
KR20150056788A (ko) 2012-09-19 2015-05-27 애브비 바이오테라퓨틱스 인크. 면역원성이 감소된 항체의 동정 방법
US10024844B2 (en) * 2012-12-20 2018-07-17 Hospital For Special Surgery Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN109045056A (zh) * 2018-07-04 2018-12-21 重庆第二师范学院 多药载药靶向纳米颗粒及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
JP2017522540A (ja) * 2014-05-09 2017-08-10 ザ ジャクソン ラボラトリーＴｈｅ Ｊａｃｋｓｏｎ Ｌａｂｏｒａｔｏｒｙ ｉＲＨＯＭポリペプチドの活性を変化させる化合物を同定する方法及びその使用
JP2022525239A (ja) * 2019-04-09 2022-05-11 ニューヨーク ソサイアティ フォー ザ リリーフ オブ ザ ラプチャード アンド クリップルド メインテイニング ザ ホスピタル フォー スペシャル サージェリー ｉＲｈｏｍ２のタンパク質バインダー

Also Published As

Publication number Publication date
JP2025179064A (ja) 2025-12-09
CN115151270A (zh) 2022-10-04
US20240287172A1 (en) 2024-08-29
AU2020360849A1 (en) 2022-04-14
EP4037699A1 (en) 2022-08-10
WO2021064009A1 (en) 2021-04-08
CA3151450A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
CN111526888B (zh) 抗tigit抗体及其作为治疗和诊断的用途
JP2022191318A (ja) 抗ｇｐｃ３抗体
JP6847037B2 (ja) 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
CN113651888B (zh) Il-11的抗体及其应用
MX2014013590A (es) Anticuerpos monoclonales multiespecificos.
JP2025179064A (ja) ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー
AU2017205900B2 (en) Therapeutic anti-CD9 antibody
JP2019163254A (ja) レクチン様酸化ｌｄｌ受容体１抗体および使用法
JP7285957B2 (ja) ｉＲｈｏｍ２のタンパク質バインダー
US11644459B2 (en) Method for selecting biological binding molecules
US11505614B2 (en) Antibodies binding to soluble BCMA
US20240174744A1 (en) Methods of treatment using protein binders to irhom2 epitopes
US12404345B2 (en) Humanized antibodies against iRHOM2
TW202246321A (zh) 抗pt217 tau抗體
KR20240161970A (ko) 항-par2 항체
CN118613506A (zh) 一种抗原结合蛋白及其用途
JP2024534706A (ja) 二重特異性抗体及びその使用
US20230159652A1 (en) Transferrin receptor 1 targeting for carcinogenesis prevention
EA051567B1 (ru) Гуманизированные антитела против irhom2
CN117222669A (zh) 针对iRhom2的人源化抗体
CN119390838B (zh) 一种靶向ccr7的纳米抗体及其制备与应用
CN113372445B (zh) 一种抗pd-1单克隆抗体
JPH08143598A (ja) 抗Ｔｉｅモノクローナル抗体及びハイブリドーマ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910